%0 Journal Article
%A Anker, Markus S
%A Mahabadi, Amir A
%A Totzeck, Matthias
%A Tewes, Mitra
%A Mincu, Raluca
%A Khan, Muhammad Shahzeb
%A Butler, Javed
%A Keller, Ulrich
%A Ahn, Johann
%A Bullinger, Lars
%A Modest, Dominik P
%A Landmesser, Ulf
%A Lehmann, Lorenz H
%A Bercker, Sven
%A Laufs, Ulrich
%A Böhm, Michael
%A Merkely, Bela
%A Diek, Monika
%A Heise, Tim
%A Hellmich, Martin
%A Placzek, Marius
%A Friede, Tim
%A Anker, Stefan D
%A Rassaf, Tienush
%T Randomized investigation of heart failure therapy in patients with advanced cancer at risk of cardiac wasting: Rationale and design of the EMPATICC trial.
%J European journal of heart failure
%V 27
%N 10
%@ 1388-9842
%C Oxford
%I Wiley
%M DKFZ-2025-01785
%P 1905-1917
%D 2025
%Z  2025 Oct;27(10):1905-1917
%X End-stage cancer may resemble a heart failure (HF)-like phenotype marked by cardiac wasting, dysfunction, and symptoms such as dyspnoea, congestion, and impaired physical function. The EMPATICC (EMPower the heArt of patients with TermInal Cancer using Cardiac medicines) trial evaluates the safety and efficacy of optimized HF therapy in patients with advanced cancer to improve self-care ability.EMPATICC is a multicentre, investigator-initiated, randomized, double-blind, controlled, proof-of-concept trial employing a joint cardio-oncology care approach. Patients were randomized 1:1 to optimized HF therapy (sacubitril/valsartan, empagliflozin, ivabradine, ferric carboxymaltose) plus usual care, or usual care alone, for 30 days, followed by a 30-day open-label extension. Eligible patients had stage IV solid tumours (per Union for International Cancer Control), were receiving palliative care, had a 1-6 month life expectancy, and were on optimized analgesia. At baseline, first patients had to meet ≥2 criteria of the following indicating cardiovascular risk: heart rate ≥70 bpm, N-terminal pro-B-type natriuretic peptide ≥600 pg/ml, elevated high-sensitivity troponin, left ventricular ejection fraction <55
%K Cardiac wasting (Other)
%K Clinical trial (Other)
%K End‐stage cancer (Other)
%K Heart failure therapy (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40857084
%R 10.1002/ejhf.3799
%U https://inrepo02.dkfz.de/record/304122